Sevabertinib Shows Antitumour Activity in Patients with Locally Advanced or Metastatic HER2-mutated NSCLC By Ogkologos - November 14, 2025 227 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SOHO-01 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Trastuzumab Deruxtecan Leads to Longer PFS and OS Compared with Chemotherapy... July 14, 2022 Strong Independent Association of TILs with OS for Patients with ERBB2-positive... February 26, 2025 Only a Quarter of Phase III Studies Demonstrated Improved QoL in... July 18, 2022 FDA Approves Pralsetinib for RET-Altered Thyroid Cancers December 2, 2020 Load more HOT NEWS Adjuvant Nivolumab Plus Ipilimumab Combination Does Not Improve RFS Over Nivolumab... Finding Purpose in Sharing Your Story: A Q&A With Esophageal Cancer... Bringing the Cancer Community Back Together at ASCO Annual Meeting: Why... When He Said His Mother-In-Law Was Going To Live In The...
